Back to Journals » Patient Preference and Adherence » Volume 6

Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients

Authors Zecca C, Yavalkar, Gobbi C

Received 9 May 2012

Accepted for publication 15 May 2012

Published 8 August 2012 Volume 2012:6 Pages 565—567

DOI https://doi.org/10.2147/PPA.S33727

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Chiara Zecca,1 Nikhil Yawalkar,2 Claudio Gobbi1

1Neurocenter of Southern Switzerland, Lugano, 2Department of Dermatology, Bern University Hospital, Bern, Switzerland

Background: The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence.
Methods: Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the established (250 µg) INF-1b dose in half (0.5 mL) the standard diluent (1.0 mL, 0.54% sodium chloride solution), and were followed for 9 months.
Results: Halving the volume of the treatment diluent was associated with significant improvement of skin side effects profile in all patients. The improvement was sustained for 9 months.
Conclusion: Halving the volume of the INF-1b diluent could represent a different strategy to optimize skin tolerability and adherence in some multiple sclerosis patients.

Keywords: multiple sclerosis, interferon, treatment tolerability, side effects, skin reactions

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]